Israeli researchers from the government-run Israel Institute for Biological Research (IIBR) indicated over the weekend that a vaccine they developed for SARS CoV-2, the virus that causes COVID-19, has been found to be effective in trials involving hamsters, paving the way for testing with humans.
The IIBR, a governmental research center specializing in biology, chemistry and environmental sciences that falls under the jurisdiction of the Prime Minister’s Office, was first tapped by Prime Minister Benjamin Netanyahu tapped in early February to begin development on producing a vaccine.
In early April, the center reported “significant progress” on the vaccine and initial trials on rodents. The secretive institute, based in Ness Ziona, has also been working on researching potential treatments and in early May announced that it made a breakthrough on a treatment involving a discovered antibody that neutralizes the virus. That same month, it further announced that researchers found that a combination of two existing antiviral drugs for Gaucher disease appears to inhibit the growth of SARS CoV-2, and may work against other viral infections, including a common flu strain.
According to the researchers’ most recent findings on a vaccine, a single dose was able to “protect hamsters against SARS-CoV-2” and showed “rapid and potent induction of neutralizing antibodies against SARS-CoV-2.”
The study, published in bioRxiv on Friday, has not yet been peer-reviewed.
The scientists say they designed a vaccine candidate using vesicular stomatitis virus (VSV), an animal virus that does not cause disease in humans, and in which the spike protein was replaced with that of SARS-CoV-2. VSV is also the basis for a separate, effective vaccine against the Ebola virus.
The vaccine, which the Israeli scientists called recombinant VSV-ΔG-spike or rVSV-ΔG-spike, was tested on golden Syrian hamsters and was shown to be “safe, well-tolerated, elicits antibodies, [is] able to bind and neutralize SARSCoV-2 efficiently, and offers protection from high-dose SARS-CoV-2 challenge in concordance with viral clearance,” according to the study.
Hamsters that were infected with SARS CoV-2 and were unvaccinated displayed rapid deterioration, significant weight loss and extensive lung damage following the monitoring process in which the disease took hold, while those immunized did not show significant signs of morbidity and gained body weight, the study showed. The vaccinated hamsters also developed antibodies.
“The vaccination provided protection against SARS-CoV-2 inoculation, as manifested in the rapid return to normal physiological parameters lung protection and rapid viral clearance. These results pave the way for further examination of rVSV-ΔGspike in clinical trials as a vaccine against SARS-CoV-2,” the researchers wrote.
A number of Israeli scientific teams and over 100 groups and organizations worldwide are currently working to develop a vaccine or a treatment for COVID-19. Thirteen are in clinical evaluation including a vaccine candidate developed by the University of Oxford which recently signed a distribution agreement with drugmaker AstraZeneca.
Massachusetts-based company Moderna was the first to develop an experimental vaccine for COVID-19 that went into trial quickly, and the company is rapidly making progress. Last week, Netanyahu announced that Israel signed an agreement with Moderna that will allow it to purchase vaccine doses should they become available as soon as next year.
In late April, Israeli scientists at the Migal Galilee Research Institute formed a new company, MigVax, to further adapt a vaccine they developed for a deadly coronavirus affecting poultry for human use. The scientists had been working for four years to develop a vaccine for IBV (Infectious Bronchitis Virus) which affects the respiratory tract, gut, kidney and reproductive systems of domestic fowl.
MigVax raised $12 million in an investment round led by OurCrowd for further development of the vaccine and said it hopes to begin clinical trials this summer.
ARTICLE FROM: https://nocamels.com/2020/06/israeli-covid-19-vaccine-effective-animal-trial/